Table 2:

Selected ongoing clinical trials of first generation Jakinibs

Agent	Specificity	Disease
Tofacitinib	JAK1/JAK2/JAK3	Down’s Syndrome: NCT04246372 Covid-19: NCT04332042, NCT04415151, NCT04390061, NCT04469114 Inflammatory Eye Disease (Uveitis & Scleritis): NCT03580343 Sjogren’s Syndrome: NCT04496960 SLE: NCT03288324
Ruxolitinib*	JAK1/JAK2	Covid-19: NCT04348071, NCT04477993, NCT04414098, NCT04359290, NCT04377620, NCT04348695, NCT04374149, NCT04424056, NCT04338958, NCT04403243, NCT04334044 Vitiligo: NCT04530344, NCT04057573, NCT04052425, NCT03099304 Thrombocythemia and Polycythemia Vera: NCT04644211, NCT04116502, NCT02962388, NCT03669965, NCT02577926, NCT03952039, NCT04455841 Hypereosinophilic Syndrome or Primary Eosinophilic Disorders: NCT03801434, NCT00044304 AD: NCT03745638 Hidradenitis Suppurativa: NCT04414514
Baricitinib	JAK1/JAK2	Covid-19: NCT04340232, NCT04320277, NCT04399798, NCT04421027, NCT04393051, NCT04373044, NCT04640168, NCT04321993 AA: NCT03570749, NCT03899259 JIA: NCT03773965, NCT04088396, NCT03773978 SLE: NCT03843125, NCT03616964, NCT03616912 AD: NCT03559270, NCT03952559, NCT03435081, NCT03334435, NCT03428100 GvHD: NCT02759731 Giant Cell Arteritis: NCT03026504 Uveitis: NCT04088409 Aicardi Goutieres Syndrome: NCT03921554 Idiopathic Inflammatory Myopathies: NCT04208464 PMR: NCT04027101
Fedratinib	JAK2/FLT3/RET/BRD4	Myelofibrosis/Polycythemia Vera: NCT03755518, NCT03952039, NCT04282187, NCT04446650, NCT04629508, NCT04562870, NCT04370301
Delgocitinib	JAK1/JAK2/JAK3/TYK2	AD: NCT03826901, NCT03725722 Chronic Hand Eczema: NCT03683719
CTP-543	JAK1/JAK2	AA: NCT03898479, NCT04518995

^*Trials for cancer and/or malignancies have been excluded

AA, alopecia areata; AD, atopic dermatitis; GvHD, graft-versus-host disease; JIA, juvenile idiopathic arthritis; MPN, myeloproliferative neoplasms; PMR, polymyalgia rheumatica; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; UC, ulcerative colitis